Market revenue in 2020 | USD 4,695.9 million |
Market revenue in 2028 | USD 8,324.3 million |
Growth rate | 7.4% (CAGR from 2020 to 2028) |
Largest segment | Mental health |
Fastest growing segment | CNS Cancer |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer |
Key market players worldwide | Biogen Inc, Otsuka Pharmaceutical, Eli Lilly and Co, Merck & Co Inc, AstraZeneca PLC, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Johnson & Johnson, Pfizer Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to central nervous system therapeutic market will help companies and investors design strategic landscapes.
Mental health was the largest segment with a revenue share of 49.53% in 2020. Horizon Databook has segmented the China central nervous system therapeutic market based on neurovascular diseases, cns trauma, mental health, neurodegenerative diseases, infectious diseases, cns cancer covering the revenue growth of each sub-segment from 2018 to 2028.
Increase in prevalence of neurological conditions, growth in manufacturing of healthcare products, and increase is healthcare expenditure in China are factors boosting market growth. Major pharmaceutical companies in the country are adopting market strategies, such as new product development and licensing, to strengthen their position locally.
For instance, in in November 2019, Amgen tied up with China’s BeiGene by paying USD 2.7 billion to acquire 20.5% stake in the company. The deal will help enhance distribution network of Amgen in the country.
Large number of local players involved in manufacturing of drugs and development of novel therapies for treatment of these disorders is expected to drive the market. For instance, in November 2019, China’s National Medical Product Administration.
Horizon Databook provides a detailed overview of country-level data and insights on the China central nervous system therapeutic market , including forecasts for subscribers. This country databook contains high-level insights into China central nervous system therapeutic market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account